ACTIVITIES
The Vax2 Muc’s activities will cover:
A GMP improved vaccine candidate against H. pylori that induces mucosal immunity when combined with novel adjuvants and delivery systems for mucosal and parenteral immunisation,
Advanced animal models providing correlates of immunity and protection to guide clinical trials,
A phase I clinical trial with improved design for a vaccine candidate against H. pylori as Proof-of-Concept for new vaccine strategies for yet unmet medical needs (i.e. most gastrointestinal pathogens),
An advanced GMP manufacturing know-how on complex subunit vaccine production to reduce costs and time,
An improved induction of mucosal immunity by innovative vaccine technologies and strategies against H. pylori and other gastrointestinal/antimicrobial resistance pathogens to prevent community-onset mucosal bacterial diseases as well as nosocomial diseases in high-risk populations.
With this, Vax2Muc will significantly contribute to reducing disease burden from infectious diseases and mortality from gastric cancer, will benefit health care systems and increase epidemic preparedness, will benefit citizens in the EU and worldwide from reduced (cross-border) health threat of antimicrobial resistance pathogens and will benefit patients and citizens by protection against H. pylori and mucosal pathogens.